ARL67156 (FPL 67156) trisodium hydrate is a selective ecto-ATPase inhibitor. ARL67156 trisodium hydrate is a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with K i s of 11, 18 and 12 μM, respectively. ARL67156 trisodium hydrate can be usedAppearance:SolidIC50& Target:Ki: 11 μM (NTPDase1), 18 μM (NTPDase3), 12 μM (NPP1)In Vitro:ARL67156 trisodium hydrate (1-100 μM) potentiates neurogenic contractions in a concentration-dependent manner. ARL67156 trisodium hydrate (10 μg/mL, 24 h) increases the surface expression of CXCR3 on ATP-treated HMC-1 cells. ARL67156 trisodium hIn Vivo:ARL67156 trisodium hydrate (1.1 μg/kg/day, administered with osmotic pumps implanted subcutaneously, for 28 days) prevents the development of calcific aortic valve disease in Warfarin (HY-B0687)-treated rats. ARL67156 trisodium hydrate (intraperitoneBiological Activity:ARL67156 (FPL 67156) trisodium hydrate is a selective ecto-ATPase inhibitor. ARL67156 trisodium hydrate is a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with K i s of 11, 18 and 12u2009μM, respectively. ARL67156 trisodium hydrate can be u. Specification: ≥99% Molecular Formula: C15H23Br2N5Na3O13P3 Molecular Weight: 834.61
- UPC:
- 51162743
- Condition:
- New
- Availability:
- 8-12 weeks
- Weight:
- 1.09 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- A658604-1mg
- Product Size:
- 1mg
